

Errata – bakalářská práce

Příprava rekombinantních protilátek s využitím metod proteinového inženýrství

Josef Šulc

Praha 2019

Strana 66, bod 2:

Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 68, 394–424 (2018).

→

Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for Clinicians* 68, 394–424 (2018).

Strana 66, bod 6:

Sácha, P. et al. Expression of glutamate carboxypeptidase II in human brain. *Neuroscience* 144, 1361–1372 (2007).

→

Sácha, P., Zámečník, J., Barinka, C., Hlouchová, K., Vícha, A., Mlcochová, P., Hilgert, I., Eckschlager, T. & Konvalinka, J. Expression of glutamate carboxypeptidase II in human brain. *Neuroscience* 144, 1361–1372 (2007).

Strana 66, bod 7:

Chang, S. S. et al. Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature. *Cancer Res* 59, 3192–3198 (1999).

→

Chang, S. S., Reuter, V. E., Heston, W. D. W., Bander, N. H., Grauer, L. S. & Gaudin, P. B. Five Different Anti-Prostate-specific Membrane Antigen (PSMA) Antibodies Confirm PSMA Expression in Tumor-associated Neovasculature. *Cancer Res* 59, 3192–3198 (1999).

Strana 67, bod 12:

Barinka, C. et al. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. *Protein Sci* 13, 1627–1635 (2004).

→

Barinka, C., Šácha, P., Sklenář, J., Man, P., Bezouška, K., Slusher, B. S. & Konvalinka, J. Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. *Protein Sci* 13, 1627–1635 (2004).

Strana 67, bod 13:

Mesters, J. R. et al. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. *The EMBO Journal* 25, 1375–1384 (2006).

→

Mesters, J. R., Barinka, C., Li, W., Tsukamoto, T., Majer, P., Slusher, B. S., Konvalinka, J. & Hilgenfeld, R. Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. *The EMBO Journal* 25, 1375–1384 (2006).

Strana 68, bod 23:

Ellis, R. J. et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 81, 29–34 (2011).

→

Ellis, R. J., Kaminsky, D. A., Zhou, E. H., Fu, P., Chen, W.-D., Brelin, A., Faulhaber, P. F. & Bodner, D. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. *Int. J. Radiat. Oncol. Biol. Phys.* 81, 29–34 (2011).

Strana 68, bod 26:

Vallabhajosula, S. et al. Pharmacokinetics and biodistribution of ¹¹¹In- and ¹⁷⁷Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of ⁹⁰Y-J591 radiation dosimetry based on ¹¹¹In or ¹⁷⁷Lu? *J. Nucl. Med.* 46, 634–641 (2005).

→

Vallabhajosula, S., Kuji, I., Hamacher, K. A., Konishi, S., Kostakoglu, L., Kothari, P. A., Milowski, M. I., Nanus, D. M., Bander, N. H. & Goldsmith, S. J. Pharmacokinetics and biodistribution of ¹¹¹In- and ¹⁷⁷Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of ⁹⁰Y-J591 radiation dosimetry based on ¹¹¹In or ¹⁷⁷Lu? *J. Nucl. Med.* 46, 634–641 (2005).

Strana 68, bod 27:

Smith-Jones, P. M. et al. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. *Cancer Res.* 60, 5237–5243 (2000).

→

Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D. & Bander, N. H. In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. *Cancer Res.* 60, 5237–5243 (2000).

Strana 69, bod 31:

Bird, R. E. et al. Single-chain antigen-binding proteins. *Science* 242, 423–426 (1988).

→

Bird, R. E., Hardman, K. D., Jacobson, J. W., Johnson, S., Kaufman, B. M., Lee, S. M., Lee, T., Pope, S. H., Riordan, G. S. & Whitlow, M. Single-chain antigen-binding proteins. *Science* 242, 423–426 (1988).

Strana 69, bod 34:

Nováková, Z. et al. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools. *The Prostate* 77, 749–764 (2017).

→

Nováková, Z., Foss, C. A., Copeland, B. T., Morath, V., Baranová, P., Havlínová, B., Skerra, A., Pomper, M. G. & Barinka, C. Novel Monoclonal Antibodies Recognizing Human Prostate-Specific Membrane Antigen (PSMA) as Research and Theranostic Tools. *The Prostate* 77, 749–764 (2017).